Soleno Begin Period Cash Flow from 2010 to 2024
| SLNO Stock | USD 51.16 1.16 2.32% |
Begin Period Cash Flow | First Reported 2013-03-31 | Previous Quarter 42.8 M | Current Value 57 M | Quarterly Volatility 27.9 M |
Check Soleno Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Soleno Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.8 M, Interest Expense of 282.1 K or Selling General Administrative of 7.4 M, as well as many indicators such as Dividend Yield of 0.0, Ptb Ratio of 4.43 or Days Sales Outstanding of 139. Soleno financial statements analysis is a perfect complement when working with Soleno Therapeutics Valuation or Volatility modules.
Soleno | Begin Period Cash Flow |
Latest Soleno Therapeutics' Begin Period Cash Flow Growth Pattern
Below is the plot of the Begin Period Cash Flow of Soleno Therapeutics over the last few years. It is the amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. Soleno Therapeutics' Begin Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Soleno Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Begin Period Cash Flow | 10 Years Trend |
|
Begin Period Cash Flow |
| Timeline |
Soleno Begin Period Cash Flow Regression Statistics
| Arithmetic Mean | 12,188,442 | |
| Geometric Mean | 5,570,001 | |
| Coefficient Of Variation | 108.75 | |
| Mean Deviation | 10,136,589 | |
| Median | 7,956,710 | |
| Standard Deviation | 13,254,541 | |
| Sample Variance | 175.7T | |
| Range | 48.6M | |
| R-Value | 0.70 | |
| Mean Square Error | 97.4T | |
| R-Squared | 0.49 | |
| Significance | 0 | |
| Slope | 2,064,854 | |
| Total Sum of Squares | 2459.6T |
Soleno Begin Period Cash Flow History
About Soleno Therapeutics Financial Statements
Soleno Therapeutics investors utilize fundamental indicators, such as Begin Period Cash Flow, to predict how Soleno Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Begin Period Cash Flow | 14.6 M | 15.2 M |
Pair Trading with Soleno Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Soleno Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Soleno Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Soleno Stock
| 0.6 | ME | 23Andme Holding | PairCorr |
| 0.5 | VALN | Valneva SE ADR | PairCorr |
| 0.44 | A | Agilent Technologies | PairCorr |
| 0.42 | DOMH | Dominari Holdings | PairCorr |
| 0.35 | DRMA | Dermata Therapeutics | PairCorr |
The ability to find closely correlated positions to Soleno Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Soleno Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Soleno Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Soleno Therapeutics to buy it.
The correlation of Soleno Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Soleno Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Soleno Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Soleno Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Soleno Therapeutics Correlation against competitors. To learn how to invest in Soleno Stock, please use our How to Invest in Soleno Therapeutics guide.You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Soleno Therapeutics. If investors know Soleno will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Soleno Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.79) | Return On Assets (0.48) | Return On Equity (0.91) |
The market value of Soleno Therapeutics is measured differently than its book value, which is the value of Soleno that is recorded on the company's balance sheet. Investors also form their own opinion of Soleno Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Soleno Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Soleno Therapeutics' market value can be influenced by many factors that don't directly affect Soleno Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Soleno Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Soleno Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Soleno Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.